T3 Companies’s Cidara Therapeutics CDTX Stock Holding History

T3 Companies’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,063	Closed	-$456K	–	172
2025 Q4	$456K	Buy	+2,063	New	+$333K	0.57%	37

T3 Companies's CDTX Position: Q1 2026 in Review

T3 Companies sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 2,063 shares — an estimated $456K sold.

T3 Companies first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $456K in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

T3 Companies reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
T3 Companies sold 2,063 Cidara Therapeutics shares in Q1 2026, an estimated $456K.
T3 Companies first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
T3 Companies's Cidara Therapeutics position peaked at $456K in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on T3 Companies's 13F filing for Q1 2026, filed 7 May 2026.